A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer
A phase 3 trial testing GQ1005 in HER2-positive breast cancer, now recruiting.
Overview
A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer is a phase 3 interventional study registered as NCT07673029, led by GeneQuantum Healthcare (Suzhou), and recruiting when checked on 2026-09-11. Official title: A Phase III, Multicenter, Open-label, Randomised Controlled Study Comparing GQ1005 and Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and a Taxane. Planned enrolment is 228 participants (estimated). The study started in 2025-01-10 and primary completion is expected in 2027-01-09. No results have been posted on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- TrialA Study of the Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast Cancer
Shares HER2-positive breast cancer and the tag ctgov-ingest.
- TrialIBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer
Shares HER2-positive breast cancer and the tag ctgov-ingest.
- TrialJSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer
Shares HER2-positive breast cancer and the tag ctgov-ingest.
- TrialEfficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer
Shares HER2-positive breast cancer and the tag ctgov-ingest.
- TrialA Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer
Shares HER2-positive breast cancer and the tag ctgov-ingest.
- TrialClinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer
Shares HER2-positive breast cancer and the tag ctgov-ingest.
- TrialA Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
Shares HER2-positive breast cancer and the tag ctgov-ingest.
- TrialRO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
Shares HER2-positive breast cancer and the tag ctgov-ingest.